Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:52:50.588Z.
Calculation as of: 2026-10-06T16:52:50.588Z.
Quote observation: 2026-10-06T16:50:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f0f34e1a3c3db59aa089d09e3018975893bb9567e33ddb8ff6924431e0b2b95
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$3.39B
EBITDA Yield
3.19%
TTM Avg
4.14%
3Y Avg
4.45%
5Y Avg
4.45%
Market Cap
$3.47B
EBITDA Yield
N/A
TTM Avg
9.48%
3Y Avg
9.54%
5Y Avg
9.54%
Market Cap
$3.55B
EBITDA Yield
0.35%
TTM Avg
0.19%
3Y Avg
0.19%
5Y Avg
0.19%
Market Cap
$3.60B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulse Biosciences, Inc. (PLSE) | $3.41B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.40B | 0.51% | 4.11% | 5.67% | 5.67% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 3.19% | 4.14% | 4.45% | 4.45% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.47B | N/A | 9.48% | 9.54% | 9.54% |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.32B | N/A | N/A | N/A | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | 0.35% | 0.19% | 0.19% | 0.19% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.60B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.09B | N/A | 0.89% | 0.89% | 0.89% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
